Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-01

Clinical Trial Update: A Study of Bumetanide for the Treatment of Autism Spectrum Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating bumetanide for autism spectrum disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BUMETANIDE (bumetanide)

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Autism Spectrum Disorder | Phase 2 | Status: COMPLETED